Atrium Medical Corporation announced that the 100th patient was enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). The iCARUS study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease in the iliac artery.

See original here: 
Atrium Announces 100th Patient Was Enrolled In The ICARUS Trial

Related posts:

1. Abbott Announces Positive Three-Year Data On Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International TrialAbbott (NYSE: ABT) announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully...
2. Celsion Announces Treatment Of First Patient In China In Global Phase III ThermoDox(R) Trial For Primary Liver CancerCelsion Corporation, a leading oncology drug development company, announced today that the first patient in China has been enrolled and treated as part of Celsion's global Phase III ThermoDox HEAT...
3. Hyperion Therapeutics Enrolls First Patient In Phase II Hepatic Encephalopathy TrialHyperion Therapeutics, Inc. announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The multi-center study consists of an open...
4. Adeona Announces Publication Of Results Of 160 Patient Phase 2 Clinical Trial Of Oral DnaJP1 For Rheumatoid ArthritisAdeona Pharmaceuticals, Inc. (AMEX: AEN) announced the publication in the journal Arthritis & Rheumatism of results of a 160-patient, six-month, double-blind, placebo-controlled Phase 2 clinical trial using the company's oral...
5. Algeta Announces First US Patient Randomized In ALSYMPCA Phase III Study At Tulane Cancer Center, New OrleansAlgeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase...
6. Harvest Technologies Announces Trial Results In Its India Study Using BMAC To Treat Patients With Non-Reconstructable Critical Limb IschemiaHarvest Technologies Corp. announced results from the company sponsored 60-patient clinical trial conducted at Sri Ramachandra Medical Center in Chennai, India using the company's BMAC System to treat patients with...
7. Boston Scientific Announces FDA Clearance And CE Mark For WallFlex(R) Fully Covered Esophageal StentBoston Scientific Corporation (NYSE: BSX) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex® Fully Covered...
8. VIA Pharmaceuticals Completes Patient Visits In Phase 2 Trial Of VIA-2291VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced that it has completed the last patient...
9. Agennix AG Announces Positive Results With Talactoferrin In Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial In Severe SepsisAgennix AG (FRANKFURT: AGX) (XETRA: AGX) reported results from the talactoferrin randomized, double-blind, placebo-controlled Phase 2 trial in severe sepsis. The trial evaluated talactoferrin versus placebo in 190 adult patients...
10. Spectrum Pharmaceuticals Announces Completion Of Enrollment In One Apaziquone Phase 3 Pivotal Trial For Bladder Cancer Ahead Of ScheduleSpectrum Pharmaceuticals (NasdaqGM: SPPI) today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive...
11. Oxygen Biotherapeutics, Inc. Enrolls First Patient In Traumatic Brain Injury Clinical Trial In SwitzerlandOxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM)...
12. Altair Therapeutics Announces Commencement Of A Multi-Center Phase IIa Clinical Trial Of Inhaled AIR645 To Treat AsthmaAltair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. ...
13. CytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 In Patients With Advanced Soft Tissue SarcomasCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate a multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a treatment for patients with advanced...
14. Pacira Announces Results Of Another Positive Phase III Trial In Post Operative PainPacira Pharmaceuticals, Inc., announced that its second Phase III placebo controlled study of EXPAREL(TM) (DepoBupivacaine) met its primary endpoint... ...
15. Advaxis Announces Phase II Trial Collaboration With The National Cancer InstituteAdvaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI),...